TR199501654A2 - Kimyasal bilesikler. - Google Patents
Kimyasal bilesikler.Info
- Publication number
- TR199501654A2 TR199501654A2 TR95/01654A TR9501654A TR199501654A2 TR 199501654 A2 TR199501654 A2 TR 199501654A2 TR 95/01654 A TR95/01654 A TR 95/01654A TR 9501654 A TR9501654 A TR 9501654A TR 199501654 A2 TR199501654 A2 TR 199501654A2
- Authority
- TR
- Turkey
- Prior art keywords
- enzyme
- host
- prodrug
- component
- natural
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 102000004190 Enzymes Human genes 0.000 abstract 8
- 108090000790 Enzymes Proteins 0.000 abstract 8
- 229940002612 prodrug Drugs 0.000 abstract 5
- 239000000651 prodrug Substances 0.000 abstract 5
- 239000002246 antineoplastic agent Substances 0.000 abstract 3
- 229940041181 antineoplastic drug Drugs 0.000 abstract 3
- 230000003993 interaction Effects 0.000 abstract 3
- 239000006225 natural substrate Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Nanotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9426192.2A GB9426192D0 (en) | 1994-12-23 | 1994-12-23 | Chemical compounds |
| GBGB9516810.0A GB9516810D0 (en) | 1995-08-16 | 1995-08-16 | Chemical compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TR199501654A3 TR199501654A3 (enExample) | 1996-07-21 |
| TR199501654A2 true TR199501654A2 (tr) | 1996-07-21 |
Family
ID=26306259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR95/01654A TR199501654A2 (tr) | 1994-12-23 | 1995-12-22 | Kimyasal bilesikler. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US5985281A (enExample) |
| EP (1) | EP0806964B1 (enExample) |
| JP (1) | JP3805365B2 (enExample) |
| KR (1) | KR100270650B1 (enExample) |
| CN (1) | CN1095677C (enExample) |
| AT (1) | ATE222124T1 (enExample) |
| AU (1) | AU701916B2 (enExample) |
| BR (1) | BR9510490B1 (enExample) |
| CA (1) | CA2205091A1 (enExample) |
| CZ (1) | CZ195297A3 (enExample) |
| DE (1) | DE69527805T2 (enExample) |
| ES (1) | ES2181805T3 (enExample) |
| FI (1) | FI972683A7 (enExample) |
| HU (1) | HUT77450A (enExample) |
| IL (1) | IL116511A0 (enExample) |
| MX (1) | MX9704575A (enExample) |
| NO (1) | NO972882L (enExample) |
| NZ (1) | NZ297529A (enExample) |
| PL (1) | PL184031B1 (enExample) |
| RU (1) | RU2189251C2 (enExample) |
| SK (1) | SK80997A3 (enExample) |
| TR (1) | TR199501654A2 (enExample) |
| WO (1) | WO1996020011A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1193278A (zh) | 1995-08-16 | 1998-09-16 | 曾尼卡有限公司 | 化合物 |
| SG71046A1 (en) | 1996-10-10 | 2000-03-21 | Connector Systems Tech Nv | High density connector and method of manufacture |
| AU6000698A (en) * | 1997-02-14 | 1998-09-08 | Zeneca Limited | Proteins |
| GB9703201D0 (en) * | 1997-02-15 | 1997-04-02 | Zeneca Ltd | Chemical compounds |
| GB9709421D0 (en) * | 1997-05-10 | 1997-07-02 | Zeneca Ltd | Chemical compounds |
| WO2000016808A2 (en) * | 1998-09-18 | 2000-03-30 | Immunomedics, Inc. | Antibody directed enzyme prodrug therapy (edept) with glucoronidase |
| US20040117863A1 (en) * | 1998-09-18 | 2004-06-17 | Edge Michael D. | Transgenically produced fusion proteins |
| US6361774B1 (en) | 1999-09-17 | 2002-03-26 | Immunomedics, Inc. | Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug |
| MXPA02002769A (es) * | 1999-09-17 | 2005-07-01 | Gtc Biotherapeutics Inc | Proteinas de fusion producidas transgenicamente. |
| CA2438641A1 (en) | 2001-02-15 | 2002-08-22 | King Pharmaceuticals, Inc. | Stabilized pharmaceutical and thyroid hormone compositions and method of preparation |
| US7101569B2 (en) | 2001-08-14 | 2006-09-05 | Franz G Andrew | Methods of administering levothyroxine pharmaceutical compositions |
| CA2506629A1 (en) * | 2002-11-27 | 2004-06-17 | Gtc Biotherapeutics, Inc. | Modified antibodies stably produced in milk and methods of producing same |
| US20080019905A9 (en) * | 2005-02-18 | 2008-01-24 | Strome Scott E | Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection |
| CN101484470B (zh) * | 2005-10-21 | 2014-07-23 | 阿伊沃生物制剂有限公司 | 具有增强的抗体依赖性细胞毒性活性的抗体及其生产方法和用途 |
| EP2037954A4 (en) * | 2006-06-20 | 2011-09-14 | Janssen Pharmaceutica Nv | METHOD FOR MODULATING PHARMACOKINETICS AND METABOLISM OF THERAPEUTIC USE |
| US20080031866A1 (en) * | 2006-06-20 | 2008-02-07 | Eichenbaum Gary M | Method for modulating the pharmacokinetics and metabolism of a therapeutic agent |
| WO2008041059A1 (en) | 2006-10-03 | 2008-04-10 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of mustards and related compounds with very high skin penetration rates |
| GB0709333D0 (en) * | 2007-05-15 | 2007-06-20 | Smart Targeting Ltd | Binding protein |
| EP2279003A4 (en) * | 2008-05-01 | 2013-04-03 | Gtc Biotherapeutics Inc | ANTI-CD137 ANTIBODY AS A MEANS FOR THE TREATMENT OF INFLAMMATORY DISEASES |
| US10745492B1 (en) * | 2019-04-03 | 2020-08-18 | Ark Diagnostics, Inc. | Antibodies to symmetrically dimethylated arginine analytes and use thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8705477D0 (en) * | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) * | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| GB8809616D0 (en) * | 1988-04-22 | 1988-05-25 | Cancer Res Campaign Tech | Further improvements relating to drug delivery systems |
| US5632990A (en) * | 1988-04-22 | 1997-05-27 | Cancer Research Campaign Tech. Ltd. | Treatment for tumors comprising conjugated antibody A5B7 and a prodrug |
| JP3273608B2 (ja) * | 1989-01-23 | 2002-04-08 | アクゾ・エヌ・ヴエー | 治療薬の部位特異的インビボ活性化 |
| US5433955A (en) * | 1989-01-23 | 1995-07-18 | Akzo N.V. | Site specific in vivo activation of therapeutic drugs |
| CA2127126A1 (en) * | 1992-01-30 | 1993-08-05 | Helen M. Wilks | Chiral synthesis with modified enzymes |
| GB9323429D0 (en) * | 1993-11-12 | 1994-01-05 | Wellcome Found | Therapy |
| US5389537A (en) * | 1994-01-21 | 1995-02-14 | Wisconsin Alumni Research Foundation | Nuclease having altered specificity |
-
1995
- 1995-12-21 EP EP95941214A patent/EP0806964B1/en not_active Expired - Lifetime
- 1995-12-21 DE DE69527805T patent/DE69527805T2/de not_active Expired - Lifetime
- 1995-12-21 CN CN95196986A patent/CN1095677C/zh not_active Expired - Fee Related
- 1995-12-21 KR KR1019970704250A patent/KR100270650B1/ko not_active Expired - Fee Related
- 1995-12-21 WO PCT/GB1995/002991 patent/WO1996020011A1/en not_active Ceased
- 1995-12-21 PL PL95320964A patent/PL184031B1/pl not_active IP Right Cessation
- 1995-12-21 CA CA002205091A patent/CA2205091A1/en not_active Abandoned
- 1995-12-21 FI FI972683A patent/FI972683A7/fi unknown
- 1995-12-21 SK SK809-97A patent/SK80997A3/sk unknown
- 1995-12-21 CZ CZ971952A patent/CZ195297A3/cs unknown
- 1995-12-21 NZ NZ297529A patent/NZ297529A/xx not_active IP Right Cessation
- 1995-12-21 RU RU97112396/14A patent/RU2189251C2/ru not_active IP Right Cessation
- 1995-12-21 AU AU42697/96A patent/AU701916B2/en not_active Ceased
- 1995-12-21 HU HU9702280A patent/HUT77450A/hu unknown
- 1995-12-21 AT AT95941214T patent/ATE222124T1/de not_active IP Right Cessation
- 1995-12-21 ES ES95941214T patent/ES2181805T3/es not_active Expired - Lifetime
- 1995-12-21 BR BRPI9510490-9A patent/BR9510490B1/pt not_active IP Right Cessation
- 1995-12-21 MX MX9704575A patent/MX9704575A/es not_active IP Right Cessation
- 1995-12-21 JP JP52028496A patent/JP3805365B2/ja not_active Expired - Fee Related
- 1995-12-21 US US08/860,882 patent/US5985281A/en not_active Expired - Lifetime
- 1995-12-22 IL IL11651195A patent/IL116511A0/xx not_active IP Right Cessation
- 1995-12-22 TR TR95/01654A patent/TR199501654A2/xx unknown
-
1997
- 1997-06-20 NO NO972882A patent/NO972882L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CZ195297A3 (en) | 1997-12-17 |
| US5985281A (en) | 1999-11-16 |
| WO1996020011A1 (en) | 1996-07-04 |
| JPH10511547A (ja) | 1998-11-10 |
| ATE222124T1 (de) | 2002-08-15 |
| FI972683A0 (fi) | 1997-06-19 |
| PL184031B1 (pl) | 2002-08-30 |
| MX9704575A (es) | 1997-10-31 |
| TR199501654A3 (enExample) | 1996-07-21 |
| HUT77450A (hu) | 1998-04-28 |
| BR9510490B1 (pt) | 2010-10-05 |
| RU2189251C2 (ru) | 2002-09-20 |
| DE69527805T2 (de) | 2003-04-24 |
| JP3805365B2 (ja) | 2006-08-02 |
| ES2181805T3 (es) | 2003-03-01 |
| NO972882L (no) | 1997-08-19 |
| FI972683L (fi) | 1997-06-19 |
| KR100270650B1 (ko) | 2000-11-01 |
| PL320964A1 (en) | 1997-11-24 |
| AU701916B2 (en) | 1999-02-11 |
| IL116511A0 (en) | 1996-07-23 |
| EP0806964B1 (en) | 2002-08-14 |
| SK80997A3 (en) | 1998-02-04 |
| DE69527805D1 (de) | 2002-09-19 |
| AU4269796A (en) | 1996-07-19 |
| CN1095677C (zh) | 2002-12-11 |
| CN1171054A (zh) | 1998-01-21 |
| NZ297529A (en) | 1999-07-29 |
| CA2205091A1 (en) | 1996-07-04 |
| FI972683A7 (fi) | 1997-06-19 |
| NO972882D0 (no) | 1997-06-20 |
| EP0806964A1 (en) | 1997-11-19 |
| BR9510490A (pt) | 1998-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI972683A0 (fi) | Kemiallisia yhdisteitä | |
| DE69329735D1 (de) | Peptid-kohlenwasserstoff konjugate, welche t-zell immunität bewirken | |
| OA07388A (fr) | Nouveaux conjugués associant, par liaison convalente, une enzyme et un anticorps et associations médicamenteuses utilisant lesdits conjugués. | |
| NO20014415L (no) | Medisinske preparater til behandling av <alfa>-galaktosidase- A-defisiens | |
| BR0210225A (pt) | Holotoxina do cólera imunogênica mutante, composição imunogênica, método para realçar a resposta imune de um hospedeiro vertebrado a um antìgeno, sequência de dna isolada e purificada, molécula de ácido nucleico, célula hospedeira, método para produzir uma holotoxina do cólera imunogênica mutante, e, uso de uma holotoxina do cólera mutante | |
| BR0113491A (pt) | Polinucleotìdeo e polipeptìdeo isolados, vetor de expressão, célula hospedeira, proteìna de fusão, métodos para estimular e/ou expandir células t especìficas para uma protéina de tumor, para estimular uma resposta imune em um paciente, para o tratamento de um câncer em um paciente e para inibir o desenvolvimento de um câncer em um paciente, população de célula t isolada, composição, e, uso de um componente. | |
| PT1157041E (pt) | Anticorpos para terapia e diagnostico de cancro | |
| AU4093799A (en) | Bifunctional molecules and therapies based thereon | |
| ID22689A (id) | Metode untuk mengaktifkan sel-sel yang menunjukan-sifat antigen manusia, sel-sel teraktifkan yang menunjukan sifat antigen manusia, dan penggunaannya | |
| HUP9801746A2 (hu) | Limfotoxin-alfa/béta komplexek és anti-limfotoxin-béta receptor antitestek mint tumorellenes szerek | |
| WO1999065517A3 (en) | Therapeutic compositions that produce an immune response by altering the antigen | |
| BR9610050A (pt) | Conjugado,sitemas de dois componentes combinados destinados a uso em um hospedeiro, compostos ou um sal destes famaceuticamente aceitavel,enzima,sequencia de polinucleotìdeos e de02 nucleotìdeos,vetor, célula hospedeira,processos de producão de uma enzima e de um conjugado e de tratamento de célulasneoplásticas em um hospedeiro,composicão farmaceutica e plasmìdeo | |
| DK1161250T3 (da) | Immunstimulerende bakteriemembranfraktioner i cancerbehandling | |
| AU6182994A (en) | Bifunctional glycoproteins having a modified carbohydrate complement, and their use in tumor-selective therapy | |
| MX9802809A (es) | Ureasa para el tratamiento de infecciones de helicobacter pylori. | |
| CY1108790T1 (el) | Συνθεσεις για τη θεραπεια και διαγνωση ωοθηκικου καρκινου | |
| IT1274592B (it) | Composizione farmaceutica per la terapia tumorale contenente xenoantigeni |